Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Date
Sponsor content
426 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Blenrep approved for the treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received prior therapy and in combination with pomalidomide and dexamethasone.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BLENREP belantamab mafodotin 70 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BLENREP belantamab mafodotin 100 mg powder for injection vial.
-
Prescription medicine registrationActive ingredients: Mepolizumab.
-
Prescription medicine registrationActive ingredients: belantamab mafodotin.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Oct-2025Prescription medicine evaluationActive ingredient: recombinant respiratory syncytial virus pre-fusion F protein.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd